Advancing Gene Therapy for Mitochondrial Eye Diseases: LHON and ADOA
Time: 2:15 pm
day: Day One
Details:
- Diving into the world of gene therapy and developing advanced gene therapy drugs for LHON (Leber’s Hereditary Optic Neuropathy) caused by ND4 and ND1 mutations, offering new hope for patients
- Exploring the progress of Neurophth’s NFS-01 gene therapy, currently in clinical stages, designed to target and treat LHON associated with ND4 mutations
- Discovering IND enabling gene therapy designed to combat ADOA (Autosomal Dominant Optic Atrophy), offering a promising avenue for addressing this rare genetic disorder affecting the optic nerves
